Brean Murray Raises Vertex Pharmaceuticals to Buy (VRTX)

By admin | 6 years ago

Vertex Pharmaceuticals (NASDAQ: VRTX) was upgraded by investment analysts at Brean Murray from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

Vertex Pharmaceuticals traded up 4.71% on Monday, hitting $60.86. Vertex Pharmaceuticals has a 52-week low of $26.50 and a 52-week high of $58.87. The company has a market cap of $12.833 billion and a price-to-earnings ratio of 41.34.

Vertex Pharmaceuticals last posted its quarterly earnings results on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $0.72 EPS next quarter.

Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase (NYSE: JPM) reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note to investors on Monday. Separately, analysts at JMP Securities upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. Finally, analysts at ISI Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Monday.

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

About the author